News and Trends 29 Jul 2022 VerImmune raises $2.5M to develop virus-inspired particle immunotherapies VerImmune, Inc., a U.S. biotech company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, has obtained $2.5 million in seed funding. The round was led by SeedFolio, a seed series venture capital firm. The round also included participation from U.S. and global investment venture firms such as Ulu Ventures, […] July 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Biotech startup Novasenta raises $40M to advance novel cancer therapeutics Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […] July 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jul 2022 Commercial personalized cancer cell profile developed in Taiwan Patients with stage 2 solid tumors could benefit from the world’s first commercial personalized cancer cell profiling, developed in Taiwan. Taipei-based CancerFree Biotech Ltd has developed the technology that will help stage 2 patients and above by shortening the selection process. The technology will be showcasing at US Bio 2022. This is the world’s first […] July 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 AGC Biologics announces gene therapy partnership with Altheia Science A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Step Pharma moves into oncology clinical trials Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, has announced its lead asset STP938 has cleared both an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), and a clinical trial application (CTA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means Step Pharma […] July 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 28 Jul 2022 How can vaccines keep up with evolving Covid-19 variants? Vaccines for COVID-19 have saved lives all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as booster shots and universal coronavirus vaccines. During 2021, a plethora of COVID-19 vaccines was rolled out around the world. Since then, mass […] July 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Diffusion Pharmaceuticals to start brain tumor clinical trial U.S. biopharma company Diffusion Pharmaceuticals Inc. is set to start a new phase 2 clinical trial. Entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (GBM) Patients when Administered with Standard of Care (“SOC”),” the company said the trial is a result of a collaboration with the United States […] July 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 SOTIO Biotech starts solid tumor trial SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors. The company has dosed its first patient in the AURELIO-04 combination trial of SOT101 and MSD’s (Merck & Co., Inc., Rahway, NJ) anti-PD-1 therapy KEYTRUDA (pembrolizumab). “The initiation of this phase […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Jul 2022 The race to uncloak cancer with liquid biopsies Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. An emerging crowd of biotechs is making it easier to detect and monitor cancer with liquid biopsies. The notion that a person’s blood can reveal a wealth of health information looked so shiny that the infamous blood diagnostics company […] July 27, 2022 - 10 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Pleco Therapeutics expands into U.S. and names president Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Deep Science Ventures deepens CRUK pact to co-found oncology startups The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K. Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration […] July 26, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email